Description
Indonesia In-Vitro Diagnostics Market Research Report Forecast to 2027
Market Overview
In-vitro diagnostics (IVD) are medical devices, reagents, and accessories used to perform tests on samples, (e.g., blood, urine, and tissue) taken from the human body to help detect infection, diagnose a medical condition, and prevent disease. IVD plays a major role in the early diagnosis and management of diseases. The key factors that drive the Indonesia in-vitro diagnostics market are rising prevalence of chronic & infectious diseases and growing awareness of personalized medicine. However, an unfavorable reimbursement scenario is anticipated to hamper the market growth.
In-vitro diagnostics (IVDs) are non-invasive tests performed on biological samples (for example, blood, urine, or tissues) to diagnose a disease. IVDs provide valuable information on the body’s functioning and state of health. IVD is used for the diagnosis, screening, and therapeutic monitoring of diseases. IVDs have a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple self-tests, such as those for pregnancy and glucose monitoring.
The Indonesia in-vitro diagnostics market is emerging due to the high prevalence of chronic and infectious diseases, increasing adoption of point-of-care testing, and rising collaborations between private and public organizations for the development of the healthcare sector are responsible for the growth of the Indonesia in-vitro diagnostics market. However, regulatory procedures for high/moderate-complexity tests and information and interest gap between investors and developers are likely to restrain the market growth during the forecast period. The scope of the Indonesia in-vitro diagnostics market study includes market size analysis and a detailed analysis of the manufacturer’s products and service strategies.
Market Segmentation
The market has been segmented based on product & services, technology, application and end user.
The Indonesia in-vitro diagnostics market is segmented on the basis of product & services into reagents & kits, instruments, data management, and software & services. The instruments segment is further segmented into fully automated instruments and semi-automated instruments.
The Indonesia in-vitro diagnostics market is segmented on the basis of technology into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hemostasis, hematology, and others. The others segment includes microbiology and tissue diagnostics.
Based on application, the Indonesia in-vitro diagnostics market is bifurcated into infectious diseases oncology, cardiology, autoimmune diseases, nephrology, diabetes, HIV-AIDS, drug testing, and pharmacogenomics.
Based on end user, the Indonesia in-vitro diagnostics market is segmented into hospitals, laboratories, point-of-care testing, academic institutes, and others.
Major Players
The key players of the Indonesia in-vitro diagnostics market are BD, Bio-rad Laboratories, Thermo Fisher Scientific, Biomeruix SA, and Danaher Corporation.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
4.2.2 INCREASING ADOPTION OF POINT-OF-CARE TESTING
4.2.3 RISING COLLABORATIONS BETWEEN PRIVATE AND PUBLIC ORGANIZATIONS FOR THE DEVELOPMENT OF THE HEALTHCARE SECTOR
4.3 RESTRAINTS
4.3.1 REGULATORY PROCEDURES FOR HIGH/MODERATE-COMPLEXITY TESTS
4.3.2 INFORMATION AND INTEREST GAP BETWEEN INVESTORS AND DEVELOPERS
4.4 OPPORTUNITY
4.4.1 GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON MARKET
5.3.3 IMPACT ON R&D
6 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES
6.1 OVERVIEW
6.2 REAGENTS & KITS
6.3 INSTRUMENTS
6.4 DATA MANAGEMENT
6.5 SOFTWARE & SERVICES
7 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 IMMUNOASSAY/IMMUNOCHEMISTRY
7.3 CLINICAL CHEMISTRY
7.4 MOLECULAR DIAGNOSTICS
7.5 HEMOSTASIS
7.6 HEMATOLOGY
7.7 OTHERS
8 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 INFECTIOUS DISEASES
8.3 DIABETES
8.4 ONCOLOGY
8.5 CARDIOLOGY
8.6 AUTOIMMUNE DISEASES
8.7 HIV/AIDS
8.8 DRUG TESTING
8.9 NEPHROLOGY
8.10 PHARMACOGENOMICS
8.11 OTHERS
9 INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 LABORATORIES
9.4 POINT-OF-CARE TESTING
9.5 ACADEMIC INSTITUTES
9.6 OTHERS
10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW
10.2 MAJOR PLAYERS IN THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
10.3 COMPETITIVE BENCHMARKING
10.4 MAJOR PLAYERS FINANCIAL MATRIX
10.4.1 REVENUE OF MAJOR PLAYERS, 2020
10.4.2 R&D EXPENDITURE, 2020
11 COMPANY PROFILES
11.1 F. HOFFMANN-LA ROCHE LTD
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS/SERVICES OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 SYSMEX CORPORATION
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS/SERVICES OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIES
11.3 DANAHER CORPORATION
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS/SERVICES OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 BIO-RAD LABORATORIES, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS/SERVICES OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 BIOMÉRIEUX SA
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS/SERVICES OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 BECTON, DICKINSON AND COMPANY
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS/SERVICES OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 SIEMENS
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS/SERVICES OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 THERMO FISHER SCIENTIFIC, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 QIAGEN
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS/SERVICES OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 AGILENT TECHNOLOGIES
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS/SERVICES OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
Companies Mentioned
BD, Bio-rad Laboratories, Thermo Fisher Scientific, Biomeruix SA, and Danaher Corporation.
Reviews
There are no reviews yet.